Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting

Abstract Background Antimicrobial stewardship (AMS) strategies worldwide focus on optimising the use of antibiotics. Selective susceptibility reporting is recommended as an effective AMS tool although there is a lack of representative studies investigating the impact of selective susceptibility repo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Franka Lestin-Bernstein, Ramona Harberg, Ingo Schumacher, Lutz Briedigkeit, Oliver Heese, Kristina Biedermann
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Antimicrobial stewardship (AMS) Staphylococcus aureus infection Selective reporting of susceptibility testing Selective antibiogram Recommended daily dose (RDD) Days of therapy (DOT) Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/644482b2249c45259f538d95fac9a16b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:644482b2249c45259f538d95fac9a16b
record_format	dspace
spelling	oai:doaj.org-article:644482b2249c45259f538d95fac9a16b2021-11-08T11:14:25ZStaphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting10.1186/s13756-021-01021-72047-2994https://doaj.org/article/644482b2249c45259f538d95fac9a16b2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13756-021-01021-7https://doaj.org/toc/2047-2994Abstract Background Antimicrobial stewardship (AMS) strategies worldwide focus on optimising the use of antibiotics. Selective susceptibility reporting is recommended as an effective AMS tool although there is a lack of representative studies investigating the impact of selective susceptibility reporting on antibiotic use. The aim of this study was to investigate the impact of selective susceptibility reporting of Staphylococcus aureus (S. aureus) on antibiotic consumption. Enhancing the use of narrow-spectrum beta-lactam antibiotics such as flucloxacillin/cefazolin/cefalexin is one of the main goals in optimising antibiotic therapy of S. aureus infections. Methods This interventional study with control group was conducted at a tertiary care hospital in Germany. During the one-year interventional period susceptibility reports for all methicillin-sensitive S. aureus (MSSA) were restricted to flucloxacillin/cefazolin/cefalexin, trimethoprim-sulfamethoxazole, clindamycin, gentamicin and rifampin/fosfomycin, instead of reporting all tested antibiotics. The impact of implementing selective reporting was analysed by monitoring total monthly antibiotic consumption in our hospital and in a reference hospital (recommended daily dose/100 occupied bed days: RDD/100 BD), as well as on an individual patient level by analysing days of therapy adjusted for bed days (DOT/ 100 BD) for patients with S. aureus bacteremia (SAB) and respectively skin and soft tissue infections (SSTI). Results MSSA-antibiograms were acquired for 2836 patients. The total use of narrow-spectrum beta-lactams more than doubled after implementing selective reporting (from 1.2 to 2.8 RDD/100 BD, P < 0.001). The use of intravenous flucloxacillin/cefazolin for SAB rose significantly from 52 to 75 DOT/100 BD (plus 42%), just as the use of oral cefalexin for SSTI (from 1.4 to 9.4 DOT/100 BD, from 3 to 17 of 85/88 patients). Considering the overall consumption, there was no decrease in antibiotics omitted from the antibiogram. This was probably due to their wide use for other infections. Conclusions As narrow-spectrum beta-lactams are not widely used for other infections, their increase in the overall consumption of the entire hospital was a strong indicator that selective reporting guided clinicians to an optimised antibiotic therapy of S. aureus infections. On a patient level, this assumption was verified by a significant improved treatment of S. aureus infections in the subgroups of SAB and SSTI. As useful AMS tool, we recommend implementing selective reporting rules into the national/international standards for susceptibility reporting.Franka Lestin-BernsteinRamona HarbergIngo SchumacherLutz BriedigkeitOliver HeeseKristina BiedermannBMCarticleAntimicrobial stewardship (AMS)Staphylococcus aureus infectionSelective reporting of susceptibility testingSelective antibiogramRecommended daily dose (RDD)Days of therapy (DOT)Infectious and parasitic diseasesRC109-216ENAntimicrobial Resistance and Infection Control, Vol 10, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Antimicrobial stewardship (AMS) Staphylococcus aureus infection Selective reporting of susceptibility testing Selective antibiogram Recommended daily dose (RDD) Days of therapy (DOT) Infectious and parasitic diseases RC109-216
spellingShingle	Antimicrobial stewardship (AMS) Staphylococcus aureus infection Selective reporting of susceptibility testing Selective antibiogram Recommended daily dose (RDD) Days of therapy (DOT) Infectious and parasitic diseases RC109-216 Franka Lestin-Bernstein Ramona Harberg Ingo Schumacher Lutz Briedigkeit Oliver Heese Kristina Biedermann Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
description	Abstract Background Antimicrobial stewardship (AMS) strategies worldwide focus on optimising the use of antibiotics. Selective susceptibility reporting is recommended as an effective AMS tool although there is a lack of representative studies investigating the impact of selective susceptibility reporting on antibiotic use. The aim of this study was to investigate the impact of selective susceptibility reporting of Staphylococcus aureus (S. aureus) on antibiotic consumption. Enhancing the use of narrow-spectrum beta-lactam antibiotics such as flucloxacillin/cefazolin/cefalexin is one of the main goals in optimising antibiotic therapy of S. aureus infections. Methods This interventional study with control group was conducted at a tertiary care hospital in Germany. During the one-year interventional period susceptibility reports for all methicillin-sensitive S. aureus (MSSA) were restricted to flucloxacillin/cefazolin/cefalexin, trimethoprim-sulfamethoxazole, clindamycin, gentamicin and rifampin/fosfomycin, instead of reporting all tested antibiotics. The impact of implementing selective reporting was analysed by monitoring total monthly antibiotic consumption in our hospital and in a reference hospital (recommended daily dose/100 occupied bed days: RDD/100 BD), as well as on an individual patient level by analysing days of therapy adjusted for bed days (DOT/ 100 BD) for patients with S. aureus bacteremia (SAB) and respectively skin and soft tissue infections (SSTI). Results MSSA-antibiograms were acquired for 2836 patients. The total use of narrow-spectrum beta-lactams more than doubled after implementing selective reporting (from 1.2 to 2.8 RDD/100 BD, P < 0.001). The use of intravenous flucloxacillin/cefazolin for SAB rose significantly from 52 to 75 DOT/100 BD (plus 42%), just as the use of oral cefalexin for SSTI (from 1.4 to 9.4 DOT/100 BD, from 3 to 17 of 85/88 patients). Considering the overall consumption, there was no decrease in antibiotics omitted from the antibiogram. This was probably due to their wide use for other infections. Conclusions As narrow-spectrum beta-lactams are not widely used for other infections, their increase in the overall consumption of the entire hospital was a strong indicator that selective reporting guided clinicians to an optimised antibiotic therapy of S. aureus infections. On a patient level, this assumption was verified by a significant improved treatment of S. aureus infections in the subgroups of SAB and SSTI. As useful AMS tool, we recommend implementing selective reporting rules into the national/international standards for susceptibility reporting.
format	article
author	Franka Lestin-Bernstein Ramona Harberg Ingo Schumacher Lutz Briedigkeit Oliver Heese Kristina Biedermann
author_facet	Franka Lestin-Bernstein Ramona Harberg Ingo Schumacher Lutz Briedigkeit Oliver Heese Kristina Biedermann
author_sort	Franka Lestin-Bernstein
title	Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
title_short	Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
title_full	Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
title_fullStr	Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
title_full_unstemmed	Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
title_sort	staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting
publisher	BMC
publishDate	2021
url	https://doaj.org/article/644482b2249c45259f538d95fac9a16b
work_keys_str_mv	AT frankalestinbernstein staphylococcusaureusselectivereportingofantibiogramresultsanditsimpactonantibioticuseinterventionalstudywithareferencegroupontheeffectofswitchingfromnonselectivetoselectiveantibioticreporting AT ramonaharberg staphylococcusaureusselectivereportingofantibiogramresultsanditsimpactonantibioticuseinterventionalstudywithareferencegroupontheeffectofswitchingfromnonselectivetoselectiveantibioticreporting AT ingoschumacher staphylococcusaureusselectivereportingofantibiogramresultsanditsimpactonantibioticuseinterventionalstudywithareferencegroupontheeffectofswitchingfromnonselectivetoselectiveantibioticreporting AT lutzbriedigkeit staphylococcusaureusselectivereportingofantibiogramresultsanditsimpactonantibioticuseinterventionalstudywithareferencegroupontheeffectofswitchingfromnonselectivetoselectiveantibioticreporting AT oliverheese staphylococcusaureusselectivereportingofantibiogramresultsanditsimpactonantibioticuseinterventionalstudywithareferencegroupontheeffectofswitchingfromnonselectivetoselectiveantibioticreporting AT kristinabiedermann staphylococcusaureusselectivereportingofantibiogramresultsanditsimpactonantibioticuseinterventionalstudywithareferencegroupontheeffectofswitchingfromnonselectivetoselectiveantibioticreporting
_version_	1718442338273984512

Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting

Ejemplares similares